We have opened multiple clinical sites with others lined up to screen and treat patients.
AQ4 MAGE DROPS TRIAL
With these compelling results, enrollment in our SPEARHEAD-1 trial has started well and we believe will accelerate rapidly. Elliot, our acting CMO, will speak more about this later. I witnessed firsthand the excitement amongst the sarcoma community and the interest from health care professionals has been reflective of this. Van Tine, who presented these results, refer to them as phenomenal. Recently, we presented data at ESMO, demonstrating a clear benefit for people with synovial sarcoma. Our priority remains to bring our ADP-A2M4 therapy to market in 2022 for people with sarcoma, which is a truly devastating cancer. One of the commitments that I made when I took the role was to focus on execution to bring benefit to people with cancer and value to our shareholders in the short term. This is the first quarterly call since I took over as CEO at the beginning of September. Good morning, everyone, and thank you for joining us. With that, I'll turn the call over to Adrian Rawcliffe. Bill Bertrand, our Chief Operating Officer Helen Tayton-Martin, our Chief Business Officer and Co-Founder Mike Garone, our Interim Chief Financial Officer and John Lunger, our Chief Patient Supply Officer, will all be available for Q&A after the prepared portion.
AQ4 MAGE DROPS FULL
We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements there.Īs a brief reminder, we anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.Īdrian Rawcliffe, our Chief Executive Officer and Elliot Norry, our acting Chief Medical Officer, are with me for the prepared portion of this call. Good morning, and welcome to Adaptimmune's conference call to discuss our third quarter 2019 financial results and other business updates. I would now like to hand the call over to Juli Miller. Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2019 Adaptimmune Earnings Conference Call. John Lunger - Chief Patient Supply Officer Adaptimmune Therapeutics PLC ( NASDAQ: ADAP) Q3 2019 Earnings Conference Call Novem8:00 AM ETĪdrian Rawcliffe - CEO, Principal Accounting Officer & DirectorĮlliot Norry - Acting Chief Medical Officer
0 kommentar(er)
